Results 211 to 220 of about 3,602,084 (334)

Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis. [PDF]

Int J Mol Sci, 2021
Basile U, Napodano C, Gulli F, Pocino K, Di Santo R, Todi L, Basile V, Provenzano C, Ciasca G, Marino M.   +9 more
europepmc   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

A Program of Investigation and Laboratory Research of Acrylic-Modified Earthen Mortar Used at Three Prehistoric Puebloan Sites

, 1996
Robert Lyle Hartzler
openalex   +1 more source

Laboratory investigation on the bioremediation technology for soilization of iron ore tailings. [PDF]

Sci Rep
Sui S, Zhao Y, Hai L, Fan G.
europepmc   +1 more source

A Laboratory Investigation on a Tailored Skin and Muscle Flap Variant for the Retrosigmoid Approach. [PDF]

J Neurol Surg B Skull Base, 2022
Chibbaro S, Cebula H, Zaed I, Gubian A, Todeschi J, Scibilia A, Nannavecchia B, Scheer L, Bozzi MT, Mahoudeau P, Coca A, Signorelli F, Djennaoui I, Debry C, Ganau M.   +14 more
europepmc   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Effectiveness of supplementary protocols for filling material removal after sealer ultrasonic activation - a laboratory investigation. [PDF]

Braz Oral Res
Rosa AFD, Chaves DMS, Dias-Junior LCL, Ghidini GP, Savaris JM, Silva RSD, Pereira RP, Bortoluzzi EA, Teixeira CDS, Garcia LDFR.   +9 more
europepmc   +1 more source

Epidemiological characteristics, clinical course, and laboratory investigation of pediatric COVID-19 patients in a tertiary care center in Saudi Arabia. [PDF]

Int J Pediatr Adolesc Med, 2022
Duabie B, Alfattani A, Althawadi S, Taha A, Javaid HA, Mobarak O, Albanyan E.   +6 more
europepmc   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

laboratory investigation [PDF]

, 2014
openaire   +1 more source